Market Place
Sourcing Support
EdiGene to Unveil Promising Preclinical POC Data for LEAPER™ 2.0
02 May 2023 //
BUSINESSWIRE
EdiGene to Present Efficacy Results of an Investigator Initiated Trial for ET-01
03 Nov 2022 //
BUSINESSWIRE
EdiGene Enters Research Collaboration With Peking University Cancer Hospital
13 Apr 2022 //
BUSINESSWIRE
EdiGene Obtains Worldwide License from Boston Children’s Hospital
15 Mar 2022 //
BUSINESSWIRE
EdiGene, Neukio ink R&D collaboration to develop next-gen immune cell therapies
11 Feb 2022 //
PHARMABIZ
EdiGene Announces Publication in Nature Biotechnology of LEAPER 2.0
10 Feb 2022 //
BUSINESSWIRE
EdiGene, Neukio Collaborate to Develop Next-Generation Immune Cell Therapies
09 Feb 2022 //
BUSINESSWIRE
EdiGene, Arbor Biotechnologies Announce WW Non-exclusive License Agreement
08 Feb 2022 //
BUSINESSWIRE
EdiGene Enters R&D Collaboration with Haihe Laboratory of Cell Ecosystem
24 Jan 2022 //
BUSINESSWIRE
EdiGene Enters Research Collaboration with the University of Wisconsin-Madison
09 Nov 2021 //
YAHOO
EdiGene to Present Latest Research on A Novel Surface Marker and Migration
04 Nov 2021 //
BUSINESSWIRE
EdiGene Announces Clinical Sites Activation and First Patient Enrolled
08 Sep 2021 //
BUSINESSWIRE
EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene
18 Jan 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.